Partial fatty acid oxidation (pFOX) inhibitor

Imbria Pharmaceuticals is focused on developing innovative treatments for cardiometabolic disorders, particularly through their investigational product candidate, ninerafaxstat. This drug is designed to enhance cellular energy metabolism by increasing the efficiency of energy production in the heart. Specifically, ninerafaxstat acts as a partial fatty acid oxidation (pFOX) inhibitor, which shifts the heart's substrate utilization towards glucose oxidation. This mechanism allows for greater ATP production per unit of oxygen consumed, thereby improving myocardial metabolic efficiency. The company has conducted Phase 2 clinical trials for ninerafaxstat in conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and early-stage heart failure with preserved ejection fraction, demonstrating its safety and tolerability.

In addition to ninerafaxstat, Imbria is advancing its research through various clinical trials that utilize cutting-edge methodologies. For instance, the IMPROVE-DiCE trial employs multi-nuclear and hyperpolarized MR spectroscopy to assess metabolic and energetic responses in patients with type 2 diabetes and heart failure. This innovative approach aims to quantify the effects of ninerafaxstat on cardiac energetics and function. Similarly, the IMPROVE-ISCHEMIA trial evaluates the drug's impact on patients with stable angina, focusing on myocardial blood flow and functional responses to ischemia. Through these advanced clinical studies, Imbria Pharmaceuticals is committed to translating its understanding of cellular metabolism into effective therapies for patients facing significant health challenges.

United States

Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.

Imbria Pharmaceuticals

Company Details